Could new eye injection schedule mean fewer shots for AMD patients?

This study is testing whether two different eye injection drugs (aflibercept and brolucizumab) can effectively treat wet age-related macular degeneration with fewer injections from the start. Researchers want to see if patients can go longer between treatments without losing vision benefits, potentially reducing the burden of frequent clinic visits. The study will follow 80 participants for up to two years to compare how well each drug works with this extended treatment schedule.